These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
34. Targeted next-generation sequencing for detection of PIK3CA mutations in archival tissues from patients with Klippel-Trenaunay syndrome in an Asian population : List the full names and institutional addresses for all authors. Sasaki Y, Ishikawa K, Hatanaka KC, Oyamada Y, Sakuhara Y, Shimizu T, Saito T, Murao N, Onodera T, Miura T, Maeda T, Funayama E, Hatanaka Y, Yamamoto Y, Sasaki S. Orphanet J Rare Dis; 2023 Sep 04; 18(1):270. PubMed ID: 37667289 [Abstract] [Full Text] [Related]
35. Phenotypic progression of skeletal anomalies in CLOVES syndrome. Klein S, Stroberg A, Ghahremani S, Martinez-Agosto JA. Am J Med Genet A; 2012 Jul 04; 158A(7):1690-5. PubMed ID: 22628280 [Abstract] [Full Text] [Related]
36. What is your diagnosis? Panteliades M, Silva CM, Gontijo B. An Bras Dermatol; 2016 Jul 04; 91(3):378-80. PubMed ID: 27438212 [Abstract] [Full Text] [Related]
37. Neutralization of HSF1 in cells from PIK3CA-related overgrowth spectrum patients blocks abnormal proliferation. Da Costa R, De Almeida S, Chevarin M, Hadj-Rabia S, Leclerc-Mercier S, Thauvin-Robinet C, Garrido C, Faivre L, Vabres P, Duplomb L, Jego G. Biochem Biophys Res Commun; 2020 Sep 24; 530(3):520-526. PubMed ID: 32620236 [Abstract] [Full Text] [Related]
38. Recurrent mosaic MTOR c.5930C > T (p.Thr1977Ile) variant causing megalencephaly, asymmetric polymicrogyria, and cutaneous pigmentary mosaicism: Case report and review of the literature. Handoko M, Emrick LT, Rosenfeld JA, Wang X, Tran AA, Turner A, Belmont JW, Undiagnosed Diseases Network, Lee BH, Bacino CA, Chao HT. Am J Med Genet A; 2019 Mar 24; 179(3):475-479. PubMed ID: 30569621 [Abstract] [Full Text] [Related]
39. Overgrowth syndromes and new therapies. Eng W, Hammill AM, Adams DM. Semin Pediatr Surg; 2020 Oct 24; 29(5):150974. PubMed ID: 33069285 [Abstract] [Full Text] [Related]
40. In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS). Ranieri C, Di Tommaso S, Loconte DC, Grossi V, Sanese P, Bagnulo R, Susca FC, Forte G, Peserico A, De Luisi A, Bartuli A, Selicorni A, Melis D, Lerone M, Praticò AD, Abbadessa G, Yu Y, Schwartz B, Ruggieri M, Simone C, Resta N. Neurogenetics; 2018 May 24; 19(2):77-91. PubMed ID: 29549527 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]